Basilar Occlusion Syndromes: An Update
Neurohosp 5:142-150, Demel, S.L. & Broderick, J.P., 2015
Varicella Zoster Virus Meningoencephalitis Presenting with Elsberg Syndrome without a Rash in an Immunocompetent Patient
Intern Med 54:2065-2067, Abe, M.,et al, 2015
4.5-Hour Time Window for Intravenous Thrombolysis with Recombinant Tissue-Type Plasminogen Activator is Established Firmly
Stroke 45:912-913,916, Schellinger, P.D. & Kohrmann, M., 2014
The 4.5-HourTime Window for Intravenous Thrombolysis with Intravenous Tissue-Type Plasminogen Activator is Not Firmly Established
Stroke 45:915-915,916, Wechsler, L.R., 2014
Endovascular Treatment for Acute Ischemic Stroke-Still Unproven
NEJM 368:952-955, Chimowitz,M., 2013
A Trial of Imaging Selection and Endovascular Treatment for Ischemic Stroke
NEJM 368:914-923,952, Kidwell, C.S.,et al, 2013
Endovascular Therapy after Intravenous t-PA versus t-PA Alone for Stroke
NEJM 368:893-903,952, Broderick, J.P.,et al, 2013
Results of Intravenous Thrombolysis within 4.5 to 6 Hours and Updated Results within 3 to 4.5 Hours of Onset of Acute Ischemic Stroke Recorded in the Safe Implementation of Treatment in Stroke International Stroke Thrombolysis Register (SITS-ISTR)
JAMA Neurol 70:837-844, Ahmed, N.,et al, 2013
Thrombolysis of Basilar Artery Occlusion: Impact of Baseline Ischemia and Time
Ann Neurol 73:688-694, Strbian, D.,et al, 2013
A Case-Controlled Comparison of Thrombolysis Outcomes Between Wake-Up and Known Time of Onset Ischemic Stroke Patients
Stroke 44:2226-2231, Manawadu, D.,et al, 2013
Prehospital Thrombolysis in Acute Stroke
Neurol 80:163-168, Weber, J.,et al, 2013
Time is Brain(stem) in Basilar Artery Occlusion
Stroke 43:3003-3006, Vergouwen, M.D.I.,et al, 2012
The Benefits and Harms of Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator within 6 h of Acute Ischaemic Stroke (the third international stroke trial IST-3): a Randomised Controlled Trial
Lancet 379: 2320, IST-3 collaborative group, 2012
Recombinant Tissue Plasminogen Activator for Acute Ischaemic Stroke: An Updated Systematic Review and Meta-Analysis
Lancet 379: 2364-2372, Wardlaw, J.M.,et al, 2012
A Pragmatic Approach Using Magnetic Resonance Imaging to Treat Ischemic Strokes of Unknown Onset Time in a Thrombolytic Trial
Stroke 43:2331-2335, Song, S.S.,et al, 2012
Helicopter Transport of Stroke Patients and Its Influence on Thrombolysis Rates
Stroke 42:1295-1300, Reiner-Deitemyer, V.,et al, 2011
Effects of Extending the Time Window of Thrombolysis to 4.5 Hours Observations in the Swedish Stroke Register (Riks-Stroke)
Stroke 42:2492-2497, Asplund, K.,et al, 2011
Endovascular Treatment of Acute Ischemic Stroke May Be Safely Performed With No Time Window Limit in Appropriately Selected Patients
Stroke 41:1996-2000, Abou-Chebl,A.,et al, 2010
Remote Supervision of IV-tPA for Acute Ischemic Stroke by Telemedicine or Telephone Before Transfer to a Regional Stroke Center Is Feasible and Safe
Stroke 41:e18-e24, Pervez,M.,et al, 2010
Fluid-Attenuated Inversion Recovery Evolution Within 12 Hours from Stroke Onset: A Reliable Tissue Clock?
Stroke 41:250-255, 197, Ebinger,M.,et al, 2010
Time to Treatment With Intravenous Alteplase and Outcome in Stroke: An Updated Pooled Analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials
Lancet 375:1695-1703, 1667, Lees, K.R., et al, 2010
Ultraearly Thrombolysis in Acute Ischemic Stroke Is Associated with Better Outcome and Lower Mortality
Stroke 41:712-716, Strbian,D., et al, 2010
The "Golden Hour" and Acute brain Ischemia: Presenting Features and Lytic Therapy in >30000 Patients Arriving Within 60 Minutes of Stroke Onset
Stroke 41:1431-1439, Saver,J.L., et al, 2010
Expansion of the Time Window for Treatment of Acute Ischemic Stroke with Intravenous Tissue Plasminogen Activator: A Science Advisory from the American Heart Association/American Stroke Association
Stroke 40:2945-2948, del Zoppo,G.J.,et al, 2009
Intraarterial Thrombolysis Within the First Three Hours After Acute Ischemic Stroke in Selected Patients
Stroke 40:2611-2612,2615, Moonis,M., 2009
Is Intraarterial tPA Within 3 Hours the Treatment of Choice for Selected Stroke Patients? No
Stroke 40:2613-2614,2615, Lindley,R.I., 2009
Stroke Therapy Academic Industry Roundtable (STAIR) Recommendations for Extended Window Acute Stroke Therapy Trials
Stroke 40:2594-2600, Saver,J.L.,et al, 2009
Number Needed to Treat to Benefit and to Harm for Intravenous Tissue Plasminogen Activator Therapy in the 3- to 4.5-Hour Window: Joint Outcome Table Analysis of the ECASS 3 Trial
Stroke 40:2433-2437,2295, Saver,J.L.,et al, 2009
Use of MRI to Estimate the Therapeutic Window in Acute Stroke: Is Perfusion-Weighted Imaging/Diffusion-Weighted Imaging Mismatch an EPITHET for Salvageable Ischemic Brain Tissue?
Stroke 40:333-335, Toth,G. &Albers,G.W., 2009
The Ethics of Thrombolytic Trials Beyond 3 (or 4.5) Hours: Randomized Controlled Trials Are Required to Change Clinical Practice
Stroke 40:1545, Donnan,G.A. &Davis,S.M., 2009
4.5 Hours: The New Time Window for Tissue Plasminogen Activator in Stroke
Stroke 40:2266-2267, Davis,S.M. &Donnan,G.A., 2009
MR Imaging-Based Decision in Thrombolytic Therapy for Stroke on Awakening: Report of 2 Cases
AJRN 29:1314-1316, Iosif,C.,et al., 2008
Thrombolysis with Alteplase 3-4.5 h After Ischaemic Stroke (SITS-ISTR): An Observational Study
Lancet 372:1303-1309, Wahlgren,N.,et al, 2008
Thrombolysis with Alteplase 3 to 4.5 Hours After Acute Ischemic Stroke
NEJM 359:1317-1329,1393, Hacke,W.,et al, 2008
Cost-Effectiveness of Intravenous Thrombolysis With Alteplase Within a 3-Hour Window After Acute Ischemic Stroke
Stroke 38:85-89, Ehlers,L.,et al, 2007
Asymptomatic Hemorrhage After Thrombolysis May Not Be Benign: Prognosis by Hemorrhage Type in the Canadian Alteplase for Stroke Effectiveness Study Registry
Stroke 38:7579, Dzialowski,I.,et al, 2007
Comparison of CT Perfusion and Angiography and MRI in Selecting Stroke Patients for Acute Treatment
Neurol 68:694-697, Wintermark,M.,et al, 2007
Evaluation of the Clinical-Diffusion and Perfusion-Diffusion Mismatch Models in DEFUSE
Stroke 38:1826-1830,1718, Lansberg,M.G.,et al, 2007
MRI-Based and CT-Based Thrombolytic Therapy in Acute Stroke Within and Beyond Established Time Windows
Stroke 38:2640-2645, Schellinger,P.D.,et al, 2007
Intravenous Alteplase for Stroke: Beyond the Guidelines and in Particular Clinical Situations
Stroke 38:2612-2618, De Keyser,J.,et al, 2007
Population-Based Analysis of the Impact of Expanding the Time Window for Acute Stroke Treatment
Stroke 38:3213-3217, Juhl,J.,et al, 2007
An Expedited Code Stroke Protocol Is Feasible and Safe
Stroke 37:2935-2939,2863, Sattin,J.A.,et al, 2006
Can Multivariable Risk-Benefit Profiling Be Used to Select Treatment-Favorable Patients for Thrombolysis in Stroke in the 3- to 6-Hour Time Window?
Stroke 37:2963-2969, Kent,D.M.,et al, 2006
Is Penumbral Imaging Useful for Extending the Treatment Window for Intravenous Tissue Plasminogen Activator?
Ann Neurol 60:499-501, Fisher,M., 2006
Predicting Abnormal Coagulation in Ischemic Stroke: Reducing Delay in rt-PA Use
Neurol 67:1665-1667, Gottesman,R.F.,et al, 2006
Imaging-Guided Acute Ischemic Stroke Therapy: From "Time is Brain" to "Physiology is Brain"
AJNR 27:728-735, Gonzalez,R.G., 2006
Perfusion CT Helps Decision Making for Thrombolysis When There is No Clear Time of Onset
JNNP 77:417-419, Hellier,K.D.,et al, 2006
Outcome and Symptomatic Bleeding Complications of Intravenous Thrombolysis Within 6 Hours in MRI-Selected Stroke Patients
Stroke 37:852-858, Thomalla,G.,et al, 2006
Perfusion-Weighted Imaging/Diffusion-Weighted Imaging Mismatch on MRI Can Now be Used to Select Patients for Recombinant Tissue Plasminogen Activator Beyond 3 Hours
Stroke 36:1099-1100, 1100, Zivin,J.A., 2005
Perfusion-Weighted Imaging/Diffusion-Weighted Imaging Mismatch on MRI Can Now Be Used to Select Patients for Recombinant Tissue Plasminogen Activator Beyond 3 Hours
Stroke 36:1098-1099,1100, Schellinger,P.D. &Fiebach,J.B., 2005